$Bob's and Jbem's Bitchin' Bios

[rocketeer357]

Have been adding shares of FPMI at a .36 average. From their Dec 2014 PR: this Phase II trial will be closing on December 15th . To date, FluoroPharma believes it has acquired sufficient patient data allowing for the assessment of the pharmaceutical's safety and quality of FCPHA generated cardiac images in humans.

According to Thijs Spoor, Chairman and CEO of FluoroPharma, "This trial has so far produced data on image quality, the optimal time for imaging after injection, and preliminary data on myocardial blood flow. To date, no major adverse events have been seen with any patients dosed with CardioPET. As we plan for the next development steps, all of this data will now be incorporated into a thorough assessment versus other clinical comparators of SPECT and angiography. It is expected that the full data will be evaluated in a blinded read fashion and then presented early next year."

I'm hoping "early next year" is almost upon us, lol.

This presentation from the company in January lays out the case for their imaging agent pretty convincingly:

http://noble.mediasite.com/mediasite/Play/3023b31663f544ab837cb391662145721d?catalog=4c6a20e5-5fc7-46ee-917e-3aa3a03fba23

The company runs on a tight budget, with only 5 fulltime employees. The shares are trading at a 52 week low, though yesterday's PPS rise was on more volume than usual (40 k shares traded) as of late. The financials aren't very pretty, but the burn rate is low and the 30 million OS is reasonable.

IMO, phase 2 results will show superior images; at .36 a share, the risk/reward is pretty decent...